Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

Grob, Charles S.; Danforth, Alicia L.; Chopra, Gurpreet S.; Hagerty, Marycie; McKay, Charles R.; Halberstadt, Adam L.; Greer, George

doi:10.1001/archgenpsychiatry.2010.116

Cited by 913 publications

(936 citation statements)

References 29 publications

Supporting

Mentioning

775

Contrasting

Unclassified

Order By: Relevance

“…Finally, four separate studies have been published on the use of psychedelics in end-of-life anxiety associated with life threatening illness (Gasser et al, 2014;Griffiths et al, 2016;Grob et al, 2011;Ross et al, 2016). Charles Grob and colleagues, working in California, United States, gave 12 subjects (11 women) a moderate (0.2 mg/kg) dose of psilocybin and an active placebo (niacin 250 mg) several weeks apart with psychological support in a double-blind design in which subjects acted as their own control (Grob et al, 2011).…”

Section: Modern Clinical Studiesmentioning

confidence: 99%

“…Charles Grob and colleagues, working in California, United States, gave 12 subjects (11 women) a moderate (0.2 mg/kg) dose of psilocybin and an active placebo (niacin 250 mg) several weeks apart with psychological support in a double-blind design in which subjects acted as their own control (Grob et al, 2011). All subjects had advanced cancer diagnoses and DSM-IV defined acute stress disorder, generalised anxiety disorder, or adjustment disorder with anxiety because of the cancer diagnosis.…”

Section: Modern Clinical Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Psychiatry & the psychedelic drugs. Past, present & future

2018

View full text Add to dashboard Cite

a b s t r a c tThe classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and mescaline, were used extensively in psychiatry before they were placed in Schedule I of the UN Convention on Drugs in 1967. Experimentation and clinical trials undertaken prior to legal sanction suggest that they are not helpful for those with established psychotic disorders and should be avoided in those liable to develop them. However, those with so-called 'psychoneurotic' disorders sometimes benefited considerably from their tendency to 'loosen' otherwise fixed, maladaptive patterns of cognition and behaviour, particularly when given in a supportive, therapeutic setting. Pre-prohibition studies in this area were sub-optimal, although a recent systematic review in unipolar mood disorder and a meta-analysis in alcoholism have both suggested efficacy. The incidence of serious adverse events appears to be low. Since 2006, there have been several pilot trials and randomised controlled trials using psychedelics (mostly psilocybin) in various non-psychotic psychiatric disorders. These have provided encouraging results that provide initial evidence of safety and efficacy, however the regulatory and legal hurdles to licensing psychedelics as medicines are formidable. This paper summarises clinical trials using psychedelics pre and post prohibition, discusses the methodological challenges of performing good quality trials in this area and considers a strategic approach to the legal and regulatory barriers to licensing psychedelics as a treatment in mainstream psychiatry.

show abstract

Section: Modern Clinical Studiesmentioning

confidence: 99%

Section: Modern Clinical Studiesmentioning

confidence: 99%

Psychiatry & the psychedelic drugs. Past, present & future

2018

View full text Add to dashboard Cite

show abstract

“…Modern experimental studies with hallucinogens in humans resumed in the 1990s with N-N-dimethyltryptamine (DMT, ayahuasca) (18)(19)(20)(21), ketamine (21)(22)(23), and psilocybin (24,25) but not with LSD. Both LSD and psilocybin have also been recently evaluated in pilot therapeutic studies as treatments for anxiety in patients with lifethreatening diseases (11,26). Because of the continued popularity of LSD as a recreational drug and renewed interest in its therapeutic use (11,27), we reexamined the acute response to LSD in healthy subjects.…”

Section: Introductionmentioning

confidence: 99%

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects

Schmid¹,

Enzler²,

Gasser

et al. 2015

Biological Psychiatry

355

439

View full text Add to dashboard Cite

“…Less is known about interactions with other receptors. Clinically, psilocybin has been extensively studied in laboratory studies in healthy subjects and substance-assisted psychotherapy in patients (Carhart-Harris et al, 2013;Griffiths et al, 2006;Grob et al, 2011;Hasler et al, 2004). Similarly, the acute psychotropic effects of DMT have been described in controlled studies in humans (Dos Santos et al, 2011;Gouzoulis-Mayfrank et al, 2005;Winstock et al, 2014).…”

Section: Introductionmentioning

confidence: 99%